Latest news with #ThomasMeyer
Fashion Network
16-07-2025
- Business
- Fashion Network
Desigual unveils unisex capsule with Botter inspired by kinetic movement
This new launch aligns with Desigual's broader transformation strategy, which aims to reinforce its creative direction and differentiated positioning in the global fashion landscape. This evolution includes the upcoming presentation of its Studio line, set to debut with a fashion show in Barcelona on September 10. It also follows the appointment of actress Ester Expósito as the brand's new ambassador, as part of Desigual's ongoing effort to connect with new generations. Founded by Thomas Meyer in 1984, Desigual currently operates over 280 single-brand stores and is present in 107 markets through 10 sales channels. The brand reported total revenues of €332 million in fiscal 2024, driven primarily by international expansion and growth in its online channel. Botter, founded by Rushemy Botter and Lisi Herrebrugh in 2017, blends Belgian and Dutch tailoring with multicultural influences. After winning the Grand Prix at the Hyères Festival in 2018 and being finalists for the LVMH Prize, the pair took over the artistic direction of Parisian fashion house Nina Ricci, a role they held until 2022. They currently lead their namesake label while also serving as artistic directors of G-Star, a role they began in April 2024.
Associated Press
15-07-2025
- Business
- Associated Press
Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine
HAMILTON, BM / ACCESS Newswire / July 15, 2025 / Altamira Therapeutics Ltd. ('Altamira' or the 'Company') (OTCQB:CYTOF), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the Japan Patent Office Board of Appeals determined that the Company's patent application on the composition of matter and methods of use for formulations of betahistine dihydrochloride for intranasal delivery is allowable. The application covers the Company's intranasal betahistine program (AM-125). 'We are very pleased to obtain patent coverage on our AM-125 nasal spray program also in Japan, one of the largest pharma markets world-wide,' commented Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. 'To date, we have secured patent coverage for AM-125 in more than 50 countries worldwide, including key markets in North America and Europe. Through collaboration with appropriate partners, we intend to bring AM-125 to the many patients worldwide who are suffering from dizziness.' About Betahistine Betahistine, a small molecule structural analog of histamine, acts as an agonist at the H1 histamine receptor and as an antagonist at the H3 histamine receptor. Unlike histamine, it crosses the blood-brain-barrier. Betahistine is known to increase the release of histamine, acetylcholine, dopamine and norepinephrine in the brain. It increases cochlear, vestibular and cerebral blood flow and facilitates vestibular compensation and inhibits neuronal firing in the vestibular nuclei. Betahistine for oral administration is approved in about 115 countries (with the U.S. being a notable exception) for the treatment of vertigo and Meniere's disease. Despite its good safety profile, the clinical utility of orally administered Betahistine is limited due to poor bioavailability. About AM-125 AM-125 is an intranasal formulation of betahistine. Because of its ability to circumvent first-pass-metabolism, AM-125 has been shown to have 5-to-29 times higher bioavailability than orally administered betahistine. Altamira Therapeutics has been developing AM-125 for the treatment of acute vestibular syndrome (vertigo). With its incidence and prevalence increasing with age, vestibular dysfunction affects more than one third of the U.S. population 40 years of age and older. About Altamira Therapeutics Altamira Therapeutics is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The versatile delivery platform is suited for different RNA modalities, including siRNA, mRNA and circRNA, and made available to pharma or biotech companies through out-licensing. The Company has two proprietary flagship programs based on xPhore and siRNA payloads: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which owns its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: Forward-Looking Statements This press release may contain statements that constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as 'may', 'might', 'will', 'should', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'projects', 'potential', 'outlook' or 'continue', or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include but are not limited to the clinical utility of Altamira's product candidates, the timing or likelihood of regulatory filings and approvals, Altamira's intellectual property position and Altamira's financial position. These risks and uncertainties also include, but are not limited to, those described under the caption 'Risk Factors' in Altamira's Annual Report on Form 20-F for the year ended December 31, 2024, and in Altamira's other filings with the Securities Exchange Commission ('SEC'), which are available free of charge on the SEC's website at: Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. Investor Contact: [email protected] SOURCE: Altamira Therapeutics Ltd. press release
Yahoo
25-04-2025
- Business
- Yahoo
Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025
Hamilton, Bermuda, April 25, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it will host its Full Year 2024 Financial Results and Business Update Call on Wednesday, April 30, 2025. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks. Webcast Access: Event: Altamira Therapeutics Full Year 2024 Financial Results and Business Update Call Date: Wednesday, April 30, 2025 Time: 8:00 am ET Webcast URL: Registration for Call: Click on the call link and complete the online registration form. Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details. Select a method for joining the call. Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone. Call Me: Enter your phone number and click 'Call Me' for an immediate callback from the system. The call will come from a US number. The call will be in listen-only mode. A replay of the call will be available after the live event and accessible through the webcast link: About Altamira Therapeutics Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: Investor ContactHear@ in to access your portfolio
